Gilead Sciences, Inc. (GILD)

Gilead Sciences' stock price has seen significant movement in the past six months, reaching $110.67 as of June 27, 2025, a 61.30% increase from June 28, 2024. Key events impacting the stock include Q1 2025 earnings, where EPS exceeded estimates but revenue missed, leading to lowered full-year profit guidance. HIV product sales increased, while Veklury sales decreased. Analyst upgrades from Deutsche Bank and Morgan Stanley also influenced the stock. A new quarterly dividend was announced. The failure of late-stage studies for Trodelvy negatively impacted investor sentiment, while positive results from a lenacapavir study for HIV PrEP provided a boost.

Gilead Sciences experiences some demand seasonality for its products, with first-quarter sales typically reflecting a seasonal decline following a strong fourth quarter. The HIV treatment market generally exhibits consistent growth, while demand for HIV prevention products is driven by increasing awareness and access. Veklury sales are influenced by COVID-19 hospitalization rates, and liver disease sales can be affected by demand fluctuations and inventory dynamics. The company anticipates flat HIV sales in 2025 due to Medicare Part D redesign, but remains optimistic about future growth. Historically, June has shown a tendency for positive stock performance.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs. It operates within the Healthcare sector, specifically in Biotechnology, Pharmaceutics, and Drug Manufacturers - General industries. The company's primary therapeutic areas include HIV/AIDS, viral hepatitis, cancer, inflammation, and serious respiratory diseases. Major products include treatments for HIV/AIDS, COVID-19, liver diseases, hematology/oncology/cell therapy, and other conditions.

Headquartered in Foster City, California, Gilead Sciences operates in over 35 countries worldwide, offering global career opportunities across multiple continents. The company has a facility in Oceanside, California, and recently acquired additional land there to expand its manufacturing operations.

Gilead Sciences has received positive recognition for its corporate responsibility and sustainability efforts, being named one of America's Most JUST Companies and included in the Dow Jones Sustainability World Index for the third consecutive year. No significant negative events impacting the company's brand reputation were identified beyond stock price fluctuations related to pipeline news.

Institutional investors hold a significant portion of Gilead Sciences' stock, ranging from approximately 78.09% to 88%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. The Vanguard Group, Inc. is the largest single institutional shareholder, holding 9.4% of outstanding shares. Insiders own approximately 0.10%, while the general public holds between 12% and 21.81% of the company's stock.